Literature DB >> 25940252

Antimicrobial resistance in hospital-acquired gram-negative bacterial infections.

Borna Mehrad1, Nina M Clark2, George G Zhanel3, Joseph P Lynch4.   

Abstract

Aerobic gram-negative bacilli, including the family of Enterobacteriaceae and non-lactose fermenting bacteria such as Pseudomonas and Acinetobacter species, are major causes of hospital-acquired infections. The rate of antibiotic resistance among these pathogens has accelerated dramatically in recent years and has reached pandemic scale. It is no longer uncommon to encounter gram-negative infections that are untreatable using conventional antibiotics in hospitalized patients. In this review, we provide a summary of the major classes of gram-negative bacilli and their key mechanisms of antimicrobial resistance, discuss approaches to the treatment of these difficult infections, and outline methods to slow the further spread of resistance mechanisms.

Entities:  

Mesh:

Year:  2015        PMID: 25940252      PMCID: PMC4420185          DOI: 10.1378/chest.14-2171

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  76 in total

1.  Strategies to prevent ventilator-associated pneumonia in acute care hospitals.

Authors:  Susan E Coffin; Michael Klompas; David Classen; Kathleen M Arias; Kelly Podgorny; Deverick J Anderson; Helen Burstin; David P Calfee; Erik R Dubberke; Victoria Fraser; Dale N Gerding; Frances A Griffin; Peter Gross; Keith S Kaye; Evelyn Lo; Jonas Marschall; Leonard A Mermel; Lindsay Nicolle; David A Pegues; Trish M Perl; Sanjay Saint; Cassandra D Salgado; Robert A Weinstein; Robert Wise; Deborah S Yokoe
Journal:  Infect Control Hosp Epidemiol       Date:  2008-10       Impact factor: 3.254

Review 2.  Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum β-lactamases and carbapenemases).

Authors:  Joseph P Lynch; Nina M Clark; George G Zhanel
Journal:  Expert Opin Pharmacother       Date:  2013-01-15       Impact factor: 3.889

3.  Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

Authors:  Dawn M Sievert; Philip Ricks; Jonathan R Edwards; Amy Schneider; Jean Patel; Arjun Srinivasan; Alex Kallen; Brandi Limbago; Scott Fridkin
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-27       Impact factor: 3.254

4.  Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003).

Authors:  Gabriel Aisenberg; Kenneth V Rolston; Amar Safdar
Journal:  Cancer       Date:  2004-11-01       Impact factor: 6.860

5.  Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.

Authors:  David L Paterson; Wen-Chien Ko; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Robert A Bonomo; Louis B Rice; Marilyn M Wagener; Joseph G McCormack; Victor L Yu
Journal:  Clin Infect Dis       Date:  2004-06-08       Impact factor: 9.079

6.  Intensive care unit outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae controlled by cohorting patients and reinforcing infection control measures.

Authors:  C Laurent; H Rodriguez-Villalobos; F Rost; H Strale; J-L Vincent; A Deplano; M J Struelens; B Byl
Journal:  Infect Control Hosp Epidemiol       Date:  2008-06       Impact factor: 3.254

7.  Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies.

Authors:  Gopi Patel; Shirish Huprikar; Stephanie H Factor; Stephen G Jenkins; David P Calfee
Journal:  Infect Control Hosp Epidemiol       Date:  2008-12       Impact factor: 3.254

8.  Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy.

Authors:  Jose Garnacho-Montero; Marcio Sa-Borges; Jordi Sole-Violan; Fernando Barcenilla; Ana Escoresca-Ortega; Miriam Ochoa; Aurelio Cayuela; Jordi Rello
Journal:  Crit Care Med       Date:  2007-08       Impact factor: 7.598

9.  Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.

Authors:  Dana R Bowers; Yi-Xin Liew; David C Lye; Andrea L Kwa; Li-Yang Hsu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-12-21       Impact factor: 5.191

10.  Clinical features, etiology, and outcomes of community-acquired pneumonia in patients with diabetes mellitus.

Authors:  Silvana Di Yacovo; Carolina Garcia-Vidal; Diego Viasus; Jordi Adamuz; Isabel Oriol; Francesca Gili; Núria Vilarrasa; M Dolors García-Somoza; Jordi Dorca; Jordi Carratalà
Journal:  Medicine (Baltimore)       Date:  2013-01       Impact factor: 1.889

View more
  46 in total

1.  In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial.

Authors:  Gregory G Stone; Patricia A Bradford; Margaret Tawadrous; Dianna Taylor; Mary Jane Cadatal; Zhangjing Chen; Joseph W Chow
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

2.  Comprehensive volatile metabolic fingerprinting of bacterial and fungal pathogen groups.

Authors:  Christiaan A Rees; Alison Burklund; Pierre-Hugues Stefanuto; Joseph D Schwartzman; Jane E Hill
Journal:  J Breath Res       Date:  2018-01-03       Impact factor: 3.262

3.  Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.

Authors:  Ardeshir Rineh; John B Bremner; Michael R Hamblin; Anthony R Ball; George P Tegos; Michael J Kelso
Journal:  Bioorg Med Chem Lett       Date:  2018-02-24       Impact factor: 2.823

4.  Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.

Authors:  Helio S Sader; Mariana Castanheira; Dee Shortridge; Rodrigo E Mendes; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

5.  Molecular Interactions of Cephalosporins with the Deep Binding Pocket of the RND Transporter AcrB.

Authors:  Alessio Atzori; Giuliano Malloci; Jigneshkumar Dahyabhai Prajapati; Andrea Basciu; Andrea Bosin; Ulrich Kleinekathöfer; Jürg Dreier; Attilio V Vargiu; Paolo Ruggerone
Journal:  J Phys Chem B       Date:  2019-05-28       Impact factor: 2.991

6.  Microcin PDI Inhibits Antibiotic-Resistant Strains of Escherichia coli and Shigella through a Mechanism of Membrane Disruption and Protection by Homotrimer Self-Immunity.

Authors:  Shao-Yeh Lu; Telmo Graça; Johannetsy J Avillan; Zhe Zhao; Douglas R Call
Journal:  Appl Environ Microbiol       Date:  2019-05-16       Impact factor: 4.792

7.  M-CSF Mediates Host Defense during Bacterial Pneumonia by Promoting the Survival of Lung and Liver Mononuclear Phagocytes.

Authors:  Alexandra Bettina; Zhimin Zhang; Kathryn Michels; R Elaine Cagnina; Isaah S Vincent; Marie D Burdick; Alexandra Kadl; Borna Mehrad
Journal:  J Immunol       Date:  2016-05-04       Impact factor: 5.422

8.  Burkholderia Sepsis in Children as a Hospital-Acquired Infection.

Authors:  Kyu Yeun Kim; Dongeun Yong; Kyungwon Lee; Ho Seong Kim; Dong Soo Kim
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

Review 9.  Biocidal Resistance in Clinically Relevant Microbial Species: A Major Public Health Risk.

Authors:  Elaine Meade; Mark Anthony Slattery; Mary Garvey
Journal:  Pathogens       Date:  2021-05-14

10.  Educational Video Improves Knowledge about Outpatients' Usage of Antibiotics in Two Public Hospitals in Indonesia.

Authors:  Fauna Herawati; Rika Yulia; Bustanul Arifin; Ikhwan Frasetyo; Herman J Woerdenbag; Christina Avanti; Retnosari Andrajati
Journal:  Antibiotics (Basel)       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.